

Hospira – Recall of dextrose 25% injection

- On April 21, 2017, the <u>FDA announced</u> a hospital/user level recall of one lot of Hospira's <u>dextrose</u> 25% injection due to the presence of human hair found within an internal sample syringe.
- The recalled lot was distributed from February 2016 through October 2016.

Product Description	NDC #	Lot # (Expiration date)
Dextrose 25% injection, 2.5 grams (250 mg/mL), 10 mL single-dose prefilled syringe	0409-1775-10	58382EV (10/1/2017)

- Dextrose 25% injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms.
- Intravenous (IV) administration of particulate to a patient could result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or systemic allergic response to the particulate. IV administration of particulate could also result in localized phlebitis, pulmonary emboli, pulmonary granulomas, immune system dysfunction, pulmonary dysfunction, and pulmonary infarction.
- To date, Hospira has not received reports of any adverse events associated with this issue for the recalled lot.
- Healthcare providers, distributors, wholesalers, and patients should immediately check inventory, quarantine, discontinue use and distribution, and return all recalled product.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled product.
- For questions regarding this recall, contact Stericycle at 1-888-570-1678.
- For any clinical inquiries regarding this recall, contact Pfizer (Hospira is a Pfizer company) at 1-800-615-0187.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.